Tripeptide-29 – 200MG
$176.00
Tripeptide-29 is a collagen-derived tripeptide. Content size is 200mg, in the form of lyophilized powder. Peptides are sold for laboratory research use only.
Purity: 99%+ by HPLC (third-party tested)
Tested by: Vanguard Laboratory, see Certificate of Analysis
SKU: P-Tripeptide-29
Discount per Quantity
| Quantity | Discount | Price |
|---|
| 5 - 8 | 5% | $167.20 | |
| 9 + | 10% | $158.40 |
What Is Tripeptide-29?
Tripeptide-29 is a small, naturally occurring amino-acid peptide, one of the primary building blocks for collagen protein.(1) Collagen is a major component of the extracellular matrix, the network of proteins and fibers comprising connective tissues. It is considered responsible for providing structure and support to cellular complexes.
Researchers suggest Tripeptide-29 may have the potential to stimulate collagen synthesis and promote the formation of collagen fibers. In addition to its possible role in collagen synthesis, Tripeptide-29 may have other biological functions. For example, research studies have hypothesized its potential as an antioxidant, which might help protect cells from oxidative stress and damage. It may also exhibit anti-inflammatory, anti-fibrotic, and anti-melanogenic characteristics.
Specifications
| Name | Tripeptide-29 |
| Other known names | Gly-Pro-Hyp, glycyl-prolyl-hydroxyproline, collagen tripeptide |
| Sequence | Gly-Pro-Hyp (3 amino acids; Hyp = 4-hydroxyproline) |
| Molecular formula | C12H19N3O5 |
| Molecular weight | 285.3 g/mol |
| CAS number | 2239-67-0 |
| Synthesis | Solid-phase peptide synthesis, US |
| Form | Lyophilized powder |
| Amount | 200 mg |
| Purity | >99% (HPLC) |
| Storage | −20 °C, dry, protected from light |
| SKU | P-Tripeptide-29 |
What Does Research Show About Tripeptide-29?
How May Tripeptide-29 Affect Collagen Stability?
Key finding: In dermal fibroblasts, a topical collagen tripeptide prevented the accumulation of advanced glycation end products, denatured collagen and reactive oxygen species, lowered the induction of matrix metalloproteinases and raised collagen 1 levels.(2)
A study conducted on dermal fibroblasts reported that hydrolyzed type 1 collagen tripeptides exhibited promising potential in reducing oxidative stress and damage.(2) As previously noted, Tripeptide-29 appears to be the primary tripeptide that forms when hydrolyzing type 1 collagen. The hydrolysate showed potential in reducing the build-up of advanced glycation end products (AGEs), reportedly preventing the production of denatured collagen and lowering levels of reactive oxygen species. The glycation process refers to sugar molecules bonding with proteins, potentially speeding up skin cell aging by altering its mechanical properties and stability. Ultimately, the scientists suggested that tripeptide-29 “might improve [cell aging] phenotypes via the inhibition of glycation and oxidative stress, leading to a delay in cellular aging.” From an in vitro perspective, the study explored the mechanisms underpinning the observed action. It was suggested that Tripeptide-29 may reduce the production of AGEs and denatured collagen while inhibiting the activity of matrix metalloproteinases (MMPs) and enhancing collagen 1 levels in dermal fibroblasts. These results suggest that Tripeptide-29 may mitigate cell aging by preserving collagen integrity and inhibiting processes that degrade the skin matrix. Furthermore, it is indicated that Tripeptide-29 might be linked to its smaller peptide size, which is believed to support its skin penetration and bioavailability.
What Does Research Suggest About DPP-IV and Glucose Control?
Key finding: Of three collagen-derived tripeptides, Gly-Pro-Hyp (Tripeptide-29) was a true peptidic inhibitor of dipeptidyl peptidase-IV, because the enzyme could not hydrolyze its Pro-Hyp bond, and it acted as a moderately competitive inhibitor (Ki = 4.5 mM).(3)
According to researchers, Tripeptide-29 may act as a peptidic inhibitor of dipeptidyl peptidase-IV (DPP-IV) due to its potential to inhibit the hydrolysis of the Pro-Hyp bond.(3) It was considered a moderately competitive inhibitor. The scientists reported that “Gly-Pro-Hyp in the collagen hydrolysates is suggested to be mainly responsible for the DPP-IV inhibition in vitro,” inferring that Tripeptide-29 may contribute to the overall inhibitory action of collagen peptides on DPP-IV. Interestingly, Tripeptide-29 was reportedly not hydrolyzed by DPP-IV, indicating resistance to this specific enzyme. This observation might point to the peptide’s stability and efficacy in the presence of this enzyme.
Dipeptidyl peptidase-IV (DPP-IV) is a serine peptidase involved in several biological processes.(4) The enzyme is expressed on the surface of various cell types, including immune cells, epithelial cells, and endothelial cells. It is also apparently found in circulation in the liver, kidney, and intestine tissues. DPP-IV cleaves peptide bonds at the N-terminus of dipeptides, tripeptides, and smaller peptides, but not larger peptides or proteins. This specificity means it may act on various substrates, including hormones, neuropeptides, and chemokines. Some of the substrates of DPP-IV include glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and peptide YY (PYY), all of which are suggested to be involved in the regulation of glucose homeostasis and energy metabolism.(5) The cleavage of GLP-1 and GIP by DPP-IV may result in rapid inactivation and clearance from circulation. Inhibiting DPP-IV may upregulate the levels of GLP-1 and GIP, which may lead to an increase in insulin secretion, reduction in glucagon levels, lower blood glucose, and decreased appetite.(6)
How May Tripeptide-29 Affect Platelets?
Key finding: The monomeric peptide (Gly-Pro-Hyp)10, a 10-fold repeat of the Tripeptide-29 sequence, stimulated platelet shape change and weak tyrosine phosphorylation of Syk and PLCγ2 but did not induce aggregation or secretion; the authors conclude that the repeat motif is enough to activate the platelet collagen receptor GPVI.(7)
Collagen-related peptides that contain a glycine-proline-hydroxyproline repeat motif are considered to be cross-linked through cysteine residues, which may stimulate platelet aggregation and secretion through glycoprotein VI (GPVI) receptors. GPVI is a platelet receptor that scientists believe to be crucial in blood clotting or hemostasis. It is a transmembrane glycoprotein that appears to be primarily expressed on the surface of platelets, which are blood cells involved in blood clotting. GPVI is a member of the immunoglobulin (Ig) superfamily of proteins and is comprised of two subunits, alpha and beta. The alpha subunit is considered to contain the collagen-binding site, while the beta subunit is deemed responsible for signaling within the platelet. When the GPVI receptor binds to collagen, it may trigger a series of events that lead to the activation of platelets and the formation of a blood clot.
Studies suggest that the non-cross-linked form of glycine-proline-hydroxyproline, or Tripeptide-29, may induce tyrosine phosphorylation of the tyrosine kinase Syk and phospholipase C gamma2 (PLCgamma2) in platelets.(7) This may ultimately stimulate platelet aggregation to stop or prevent bleeding. Overall, the researchers report that Tripeptide-29, “present as a repeat motif, is sufficient to activate the platelet collagen receptor GPVI,” and may stimulate the formation of thrombi to prevent excessive bleeding.
Certificate of Analysis
| Batch / lot | C74203 |
| Test date | 7/15/2026 |
| Testing laboratory | Vanguard Laboratory |
| Accreditation | A2LA Certificate #6377.01.01 |
| Method | HPLC-UV/VIS (purity) |
| Purity result | 99.45% |
| Full report | Download the Tripeptide-29 COA (PDF) |
Tripeptide-29 peptide is available for research and laboratory purposes only. We offer free shipping in the US for orders over $200. Please review our Terms and Conditions before ordering.
Frequently Asked Questions
What is Tripeptide-29?
Tripeptide-29 is the collagen tripeptide glycyl-prolyl-hydroxyproline (Gly-Pro-Hyp), a sequence that repeats in the collagen triple helix.
What has Tripeptide-29 been studied for?
Research has examined Tripeptide-29 and collagen tripeptides in collagen stability, glycation and oxidative stress in dermal fibroblasts, dipeptidyl peptidase-IV inhibition and platelet collagen receptor signaling.
What is the molecular weight of Tripeptide-29?
Tripeptide-29 has the molecular formula C12H19N3O5 and a molecular weight of approximately 285.3 g/mol.
How should Tripeptide-29 be stored?
Lyophilized Tripeptide-29 should be stored at −20 °C, dry and protected from light.
Is Tripeptide-29 third-party tested?
Yes. The current batch (C74203) was tested by a third-party laboratory and showed >99% purity by HPLC. Its certificate of analysis is available on this page.
References:
- Wiśniewski, K., Artemowicz, B., Lutostańska, A., Maćkowiak, J., & Koziołkiewicz, W. (1994). Central activity of peptide Gly-Pro-Hyp–the main component of collagen degradation products mixture. Acta neurobiologiae experimentalis, 54(1), 33–38.
- Lee, Y. I., Lee, S. G., Jung, I., Suk, J., Lee, M. H., Kim, D. U., & Lee, J. H. (2022). Effect of a Topical Collagen Tripeptide on Antiaging and Inhibition of Glycation of the Skin: A Pilot Study. International journal of molecular sciences, 23(3), 1101. https://doi.org/10.3390/ijms23031101
- Hatanaka, T., Kawakami, K., & Uraji, M. (2014). Inhibitory effect of collagen-derived tripeptides on dipeptidylpeptidase-IV activity. Journal of enzyme inhibition and medicinal chemistry, 29(6), 823–828. https://doi.org/10.3109/14756366.2013.858143
- Trzaskalski, N. A., Fadzeyeva, E., & Mulvihill, E. E. (2020). Dipeptidyl Peptidase-4 at the Interface Between Inflammation and Metabolism. Clinical medicine insights. Endocrinology and diabetes, 13, 1179551420912972. https://doi.org/10.1177/1179551420912972
- Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995). Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology, 136(8), 3585–3596. https://doi.org/10.1210/endo.136.8.7628397
- Kasina, S. V. S. K., & Baradhi, K. M. (2022). Dipeptidyl Peptidase IV (DPP IV) Inhibitors. In StatPearls. StatPearls Publishing.
- Asselin, J., Knight, C. G., Farndale, R. W., Barnes, M. J., & Watson, S. P. (1999). Monomeric (glycine-proline-hydroxyproline)10 repeat sequence is a partial agonist of the platelet collagen receptor glycoprotein VI. The Biochemical journal, 339(Pt 2), 413–418. https://pubmed.ncbi.nlm.nih.gov/10191274/




